Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Midi Health vs WeightRx

Midi Health
Graded #413

Lower grade

vs+15.699999999999996
WeightRx
Graded #85

Higher grade

The verdict

WeightRx takes it — 72.1/100 to 56.4/100.

WeightRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightRx is a telehealth provider publishing compounded semaglutide at $250/mo and compounded tirzepatide at $83/mo.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWeightRx +46
45
91
Dose & formulationWeightRx +24
40
64
Clinical oversightWeightRx +4
78
82
Labs & monitoringWeightRx +1
52
53
FulfillmentMidi Health +13
78
65
Contract termsEven
55
55
Midi Health · left barWeightRx · right bar

The numbers

MetricMidi HealthWeightRx
WeighScore56.4/10072.1/100
GradeCC
Scorecard rank#413#85
SemaglutideNot disclosed$250/mo (compounded)
TirzepatideNot disclosed$83/mo (term not published, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Midi Health

Graded #413 · C

Strengths

  • Available in all 50 states
  • Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
  • Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
  • Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)

Where it loses points

  • Does not accept Medicare, Medicaid, or Medi-Cal
  • GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
  • Menopause-focused — not the right fit for men or younger women whose main goal is weight loss
WeightRx

Graded #85 · C

Strengths

  • The tirzepatide figure is published up front, and it is genuinely low against the field
  • Both molecules are offered
  • No membership charge is advertised alongside the medication rate

Where it loses points

  • The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
  • Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
  • Six- and twelve-month plans are non-refundable, and eligible refunds carry a 5% processing fee
  • No dose strength is published anywhere, so what the $83 buys is not stated
  • The named operator is Twist G Marketing, LLC rather than a clinical entity, and the terms carry a binding arbitration and class-action waiver

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard